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Abstract 
Introduction: Tension-type headache (TTH) is very common, with a lifetime prevalence in the general 
population ranging in different studies between 30% and 78%. TTH, divided into episodic and chronic types, 
introduced in the manual "International Classification of Headache Disorders"(ICHD-I), is of practical 
importance. Infrequent episodic headaches (no more than once a month) may not require drug therapy, but, on 
the contrary, frequent forms may require expensive treatment.  
Objective: To study the state of cerebral hemodynamics and cerebrovascular reactivity in patients with   
Tension-type headache and evaluate the efficacy of treatment with Phenibite using Doppler ultrasound. 
Materials and Methods: A retrospective analysis of the results of ultrasound dopplerography  of the anterior, 
middle and posterior cerebral arteries (ACA, MCA and PCA), Vertebral and Basal   (VA, BA) arteries was 
performed in 188 patients with TTH. Among them are infrequent episodic TTH - 68 (36,2%) patients, frequent 
episodic TTH - 64 (34,0%) patients, chronic TTH - 56 (29,8%) patients. The age of the subjects was 18-45 
years, among them 85 (45.2%) men and 103 (54.8%) women. The maximum systolic velocity (Vs), the end 
diastolic velocity (Vd), the resistance and pulsativity indexes (RI, PI) in all vessels were determined.  
Patients were given consent to participate in the study. 
Results: Infrequent episodic (IFE) TTH were recorded in 86.4% of cases, frequent episodic (FE) — in 88.9%, 
and chronic (Ch) TTH — in 81.6% of cases. Bilateral TTH was noted in 39.2%, frontal localization - in 35.6%, in 
the occipital region - in 25–7% of cases. The asymmetry of the maximum systolic blood flow velocity (Vs) in the 
paired arteries within 20-30% was considered a violation of cerebral hemodynamics, which was detected in 
38.7% of patients. An increase in Vs was noted in all cerebral vessels, especially in patients with FE TTH and 
chronic Ch TTH compared with the control group. 
In patients with IFE TTH the average value of RcFMt was 1.24±0.03, in patients with FE TTH - 1.25±0.02, in 
patients with Ch TTH - 1.27±0.03. In patients with TTH, hyper-responsiveness to hypercapnic test was 
detected: RcCO2 was 1.43±0.05 in the group with FE TTH; 1.39±0.07 in the group of Ch TTH and 1.37±0.04 in 
the group of IFE TTH, which indicates a tendency for the tension of the vasodilator regulation mechanism even 
in clinically insignificant forms of TTH. In the study of reactivity to the O2-test, a hyporeactive response was 
observed in the groups with FE TTH and Ch TTH (0.38±0.04 and 0.35±0.05, respectively. 
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Introduction  
 Tension-type headache is very common, with a 
lifetime prevalence in the general population ranging in 
different studies between 30% and 78%. According to 
Jensen R and Stovner (2008), the percentage of the 
adult population with an active headache disorder is 
47% for headache in general, 10% for migraine, 38% 
for tension-type headache, and 3% for chronic 
headache that lasts for more than 15 days per                  
month [1]. According to other researchers, primary                     
tension-type headaches occur in approximately 40% of 
the adult population worldwide  [2]. Central sensitization 
caused by prolonged nociceptive input from muscles is 
considered to play an important role for chronification of 
tension-type headache [3].  
 Directly and indirectly chronic tension-type 
headache (CTTH) causes high costs and considerable 
loss of quality of life. Lindelof K. et al. (2009) 5-minute 
infusion of hypertonic saline was performed in 20 
patients with CTTH and 20 healthy controls.  Were 
measured the blink reflex (BR), sensibility to pressure 
and electrical pain scores before, during and 25 min 
after the saline infusion. According to Lindelof K. et al 
(2009) the pain rating of the electrical stimuli and the 
pain score of the hypertonic saline infusion were 
significantly higher in CTTH patients than in healthy 
volunteers. The primary endpoint was the relative 
change of the blink reflex integral immediately after 
hypertonic saline infusion. It was significantly smaller in 
CTTH patients on the contralateral side compared to 
healthy volunteers, while there was no significant 
difference on the ipsilateral side [4]. 
 Neck pain is highly prevalent in the general 
population and even more prevalent in individuals with 
primary headaches. Prevalence is highest in coexistent 
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The treatment with Phenibut carried out in a step-by-step manner - during the first week the drug was applied at a 
dose of 250 mg 2 times a day, over the next 6 weeks the dose increased to 500 mg 2 times a day, then the dose 
was reduced back to 250 mg 2 times a day. Among patients with FE TTH, the frequency of headache decreased 
from 5.7±2.3 to 3.6±2.1 days/month, and in patients with Ch TTH - from 22.8±1.7 to 17.7±1,3 days/month 
(P<0,05). Influence of the drug was manifested at the initially increased RcFMt and RcCO2. A decrease in initially 
elevated RcCO2 was noted in all (FE TTH, ChTTH, IFETTH) clinical groups. However, this decrease was not 
statistically significant. 
Conclusion: In patients with TTH, an increase in the Vs is more often recorded, their asymmetry in the middle 
cerebral artery. Hyperreactivity on CO2-load is typical for patients with chronic TTH, and reflects the mobilization of 
metabolic regulation of cerebral blood flow. Conducting FMt was the most informative method for detecting 
autoregulatory disorders mainly  in patients with IFE TTH. FE TTH in patients is characterized by the presence of a 
hyperactive reaction to hypercapnic and orthostatic tests, probably due to mobilization of humoral-metabolic and 
neurogenic links of regulation. In the group of patients with chronic TTH prevails hyporeactivity for hyperventilation 
test, reflecting the depletion of vasoconstriction reserve. The use of Phenibut [(Noophen® (JSC Olainfarm, Latvia] 
in the treatment of TTH is accompanied by a decrease in the frequency of pain, and of pericranial muscle tone, 
most pronounced in patients with FE TTH. It's effectiveness is evident in the normalization of the  coefficients of 
cerebrovascular reactivity in a patients with chronic TTH. The minimal statistical significance was observed on the 
dynamics of blood flow only  in the VA. 
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M+TTH, followed by pure TTH and migraine. Myofascial 
tenderness is significantly increased in individuals with 
neck pain [5]. The ICHD-3 diagnostic criteria for chronic 
tension-type headache are summarized as follows [6]. 
 Headache occurring on ≥ 15 days per month on 
average for > 3 months (≥ 180 days per year), fulfilling 
criteria II-IV;  
II. Lasting hours to days, or unremitting;  
III. ≥ 2 of the following characteristics a. Bilateral 
location b. Pressing or tightening (non-pulsating) quality 
c. Mild or moderate intensity d. Not aggravated by 
routine physical activity;  
IV. Both of the following: a. No more than one of 
photophobia, phonophobia, or mild nausea b. Neither 
moderate or severe nausea nor vomiting;  
V. Not better accounted for by another ICHD-3 
diagnosis. 
 Tension-type headache has a high                         
socio-economic impact. Divided into episodic and chronic 
types, introduced in the manual "International 
Classification of Headache Disorders"(ICHD-I), it has 
practical importance. Infrequent episodic headaches                
(no more than once a month) may not require drug 
therapy, but, on the contrary, frequent forms may 
require expensive treatment. Chronic tension-type 
headache is a serious disease, causing greatly decreased 
quality of life and high disability [7].  Research results 
Madsen B.K. et al. (2018) show, there is a lower force 
steadiness and rate of force development (RFD)  in 
patients with the Tension-type headache (TTH) 
compared to healthy people [8].  
 In most cases, the intensity of tension-type 
headachea  is low and this leads to self-diagnosis of the 
patient and self-treatment with non-prescription drugs. 
The sooner after onset a tension-type headache is 
treated, the more effective the agent is at aborting the 
headache. Lenaerts M.E. (2009) analyzed the literature 
data on the treatment of Tension-type headaches with 
drugs such as tricyclic antidepressants and nonsteroidal 
antinflammatory drugs. Their efficacy was shown mainly 
in the treatment of episodic TTH [9].   
 In recent years several studies on the treatment 
of episodic and chronic tension-type headache have 
been published, the classification of the headaches, 
including tension-type headache, has been revised. The 
basic principles of treatment for tension- type headache 
have been developed [10].  
 The analysis was performed of the majority of 
published medical reference systems for a number of 
clinical studies on TTH. The results of these studies were 
recommendations of level A, B, or C and examples of 
good practice. According to Bendtsen L. et al. (2010) 
electromyography (EMG) biofeedback has a documented 
effect in TTH, whilst cognitive-behavioural therapy and 
relaxation training most likely are effective. Simple 
analgesics and non-steroidal anti-inflammatory drugs are 
recommended for the treatment of episodic TTH. 
Combination analgesics containing caffeine are drugs of 
second choice. Triptans, muscle relaxants and opioids 
should not be used. It is crucial to avoid frequent and 
excessive use of analgesics to prevent the development 
of medication-overuse headache. The tricyclic  
antidepressant amitriptyline is drug of first choice for the 
prophylactic treatment of chronic TTH. Mirtazapine and 
venlafaxine are drugs of second choice. The efficacy of 
the prophylactic drugs is often limited, and treatment 
may be hampered by side effects [11].  
 First-line acute treatment options for                 
tension-type headaches include acetaminophen, 
ibuprofen, naproxen sodium, ketoprofen,                             
and diclofenac [12,13]. The effectiveness of                     
pharmacotherapy for tension-type headache depends on 
the leading mechanism of pain and the effect of a drug 
on these particular mechanisms. At present, there is no 
single view on the pathogenesis of TTH. In the origin of 
TTH are involved as peripheral and central nociceptive 
mechanisms. In episodic TTH, peripheral (muscular) 
factors are most important, whereas in chronic TTH, 
pathogenetic mechanisms are multifactorial in                  
nature [14].  Also in the pathogenesis of HDN significant 
the presence of chronic emotional stress, which is 
formed under the influence of individually significant 
psychogenic factors in individuals with functional 
insufficiency of antinociceptive systems, becomes 
important [15].  
 The question of the role of vascular mechanisms 
in the development of TTH remains relevant. Some 
researchers suggest that increased potassium       
concentration, which occurs during prolonged muscle 
tension, stimulates its chemoreceptors and causes pain. 
It has also been shown that an increase in muscle 
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tension leads to a narrowing of the arterial vessels and 
the appearance of ischemia [16].  
 Among intracranial sources of headache, a part 
of the dura mater, the arteries of the brain base, and 
the extracranial arteries, which are innervated by the 1st 
branch of the trigeminal nerve, may play a certain role. 
In patients with chronic pain, a secondary role is 
assigned to the secondary effects of mediator      
mechanisms on systemic hemodynamics and, in 
particular, to the cerebral blood flow. Prolonged stress 
leads to an increase cerebral metabolism and therefore 
an increase in blood flow, which in turn requires 
adequate venous drainage. Organic or functional 
impairment of venous outflow can lead to overflow of 
venous sinuses and trigeminal nerve irritation. In this 
way, violation of the relationship between arterial and 
venous circulatory systems of the brain can be one of 
the factors leading to leading to the occurrence and 
chronic headache. Studies show the value of vascular 
mechanism, as one of the leading pathogenetic factors 
in both primary TTH and secondary its forms. 
 Drugs with antiasthenic and anxiolytic effects 
are traditionally used in the treatment of TTH. Of 
particular interest in this context is the                              
drug Phenibut - betaenyl-gammaaminobutyric acid  
hydrochloride. It has directional activating effect only on 
the GABA-B receptors, and this is precisely its mild 
anxiolytic action without adverse effects inherent in                                
benzodiazepines [17].  
 It is interesting to evaluate the efficacy of 
Phenibit (Noophen® JSC Olainfarm, Latvia) on 
cerebrovascular reactivity using Doppler ultrasound and 
various functional tests. 
Objective 
 To study the state of cerebral hemodynamics 
and cerebrovascular reactivity in patients with               
Tension-type headache and evaluate the efficacy of 
treatment with Phenibite using Doppler ultrasound. 
Materials and Methods 
 A retrospective analysis of the results of 
ultrasound dopplerography  of the anterior, middle and 
posterior cerebral arteries (ACA, MCA and PCA), 
Vertebral and Basal   (VA, BA) arteries was performed in 
188 patients with Tension-type Headache. Among them 
are infrequent episodic (IFE) TTH - 68 (36,2%) patients, 
frequent episodic (FE) TTH - 64 (34,0%) patients, 
chronic (Ch) TTH - 56 (29,8%) patients. The age of the 
subjects was 18-45 years, among them 85 (45.2%) men 
and 103 (54.8%) women. Patients were given consent 
to participate in the study. 
 When assessing the nature of the headache was 
taken into account  qualitative and quantitative 
parameters, provoking factors, accompanying   
symptoms, methods of stopping pain. The determination 
of the pericranial muscle soreness was carried out by  
palpation followed by the assessment of the Total 
Tension Scale system.  
The State of Cerebrovascular Reactivity was Assessed 
Using the Following Functional Tests 
1. hypercapnic test, reactivity coefficient (Rс CO2); 
2. hyperventilation test, reactivity coefficient (Rc О2); 
3. orthostatic test, reactivity coefficient (Rc Ot); 
4. antiorthostatic test, reactivity coefficient (Rc AОt); 
5. functional nitroglycerin test, reactivity coefficient                     
(Rc FNt), 
6. functional metabolic test, reactivity coefficient                  
(Rc FMt) 
 The control group (CG) - 50 clinically healthy 
volunteers of both sexes of appropriate age. The 
maximum systolic velocity (Vs), the end diastolic velocity  
(Vd), the resistance and pulsativity indexes (RI, PI) in all 
vessels were determined. 
 Statistical analysis and material processing was 
performed using the Statistic 6.0 software package. 
Differences recognized statistically significant at                       
P <0.05. 
Results 
 Among the surveyed, infrequent episodic (IFE) 
TTH were recorded in 86.4% of cases, frequent episodic 
(FE) — in 88.9%, and chronic (Ch) TTH — in 81.6% of 
cases. Bilateral TTH was noted in 39.2%, frontal 
localization - in 35.6%, in the occipital region - in 25–7% 
of cases. As a provoking factor for TTH, emotional 
stresses occurred in 38.4%, wearing tight headgear - in 
22.1%, combing - in 13.2% of cases, respectively. 
Nausea was observed in 11.4% of cases,                       
phonophobia - in 8.3%, vomiting - in 4.4%,        
photophobia - in 4.1%, vegetative dysfunction in 74.7%, 
emotional lability - in 67.8%, extended tendon 
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hyperreflexia without focal neurological symptoms in 
48.7% of cases, respectively (Table 1). 
 The asymmetry of the maximum systolic blood 
flow velocity (Vs) in the paired arteries within 20-30% 
was considered a violation of cerebral hemodynamics, 
which was detected in 38.7% of patients. An increase in 
Vs was noted in MCA in patients with Ch TTH and FE 
TTH compared with the control group                               
(Figure 1, 2A and B).  
 RcFMt parameters were significantly increased in 
all clinical groups. In patients with IFE TTH the average 
value of this coefficient was 1.24±0.03, in patients with 
FE TTH - 1.25±0.02, in patients with                           
Ch TTH - 1.27±0.03. 
 In patients with TTH, hyper-responsiveness to 
hypercapnic test was detected: RcCO2 was 1.43±0.05 in 
the group with FE TTH; 1.39±0.07 in the group of Ch 
TTH and 1.37±0.04 in the group of IFE TTH, which 
indicates a tendency for the tension of the vasodilator 
regulation mechanism even in clinically insignificant 
forms of TTH. In the study of reactivity to the O2-test, a 
hyporeactive response was observed in the groups with 
FE TTH and Ch TTH (0.38±0.04 and 0.35±0.05), 
respectively (Figure 3). As can be seen from Figure 3, in 
all groups, the reactivity coefficient (Rc) when 
performing functional tests using CO2 and FMt was 
significantly higher than using O2 (P <0.001). 
 As can be seen from Figure 4 similar results 
were obtained with the antiorthostatic test (RcAOt) 
compared with the results of the orthostatic (RcOt) and 
functional test with nitroglycerin (RcFNt). However, in 
the study of reactivity to orthostatic, nitroglycerin and 
antiorthostatic tests there were no significant differences 
between the parameters of patients with IF TTH, FE 
TTH, Ch TTH and  CG. 
 We have carried out a clinical doppler study of 
the influence of  Phenibut (Noophen® JSC Olainfarm, 
Latvia) on the clinical symptoms of TTH, parameters of 
cerebral hemodynamics and cerebrovascular reactivity. 
 To assess the effectiveness of Phenibut, the 
following were taken into account: frequency and 
intensity of headache, pain in the pericranial muscles, Vs 
of the cerebral arteries, Rc CO2, RcО2, RcОt, RcAОt, 
RcFMt and RcFNt in a patients with TTH before and after 
treatment. The treatment was carried out in a                       
step-by-step manner - during the first week the drug 
was applied at a dose of 250 mg 2 times a day, over the 
next 6 weeks the dose increased to 500 mg 2 times a 
day, then the dose was reduced back to 250 mg 2 times 
a day. (Figure 5) 
 As can be seen from figure 5 among patients 
with FE TTH, the frequency of headache decreased from 
5.7±2.3 to 3.6±2.1 days/month, and in patients with Ch 
TTH - from 22.8±1.7 to 17.7±1.3 days/month (P<0,05). 
 In all clinical groups, the Visual Analogue Scale 
(VAS) headache intensity indices gradually decreased 
from 3.1±1.1 points to 1.8±0.7 points in the group of 
IFE TTH, from 3.5±1.4 points to 1.9±1.1 points in the 
group of FETTH and from 7.3±2.1 points to 5.2±1.7 
points in the group of ChTTH (Figure 6).  As can be seen 
 IFE TTH FE TTH Ch TTH 
Age, years 25,7 ± 4,2 32,7 ± 6,3 38,8 ± 7,4 
Duration TTH, years 3,8 ± 2,2 6,9 ± 4,3 9,5 ± 6,1 
Frequency TTH, days/month 0,97 ± 0,3 5,7 ± 4,3 22,8 ± 7,7 ** 
The intensity of headache on VAS (Visual 
Analogue Scale), points 
3,1 ± 1,3 3,5 ± 1,4 7,3 ±2,1 * 
Soreness of the pericranial muscles, the 
average score 
1,2 ± 0,4 1,2 ± 0,6 3,3 ± 0,4 * 
Frequency of taking analgesics, days / 
month 
 0,7 ± 0,2 
  
2,3 ± 1,7 
  
8,8 ± 3,6 * 
Table 1. Clinical characteristics of patients with TTH 
(*p<0,05 ) 
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Figure 1. Parameters of Vs (cm/c) in the main cerebral arteries in a 
patients with TTH. 
A B 
Figure 2. Registration of blood flow in the left (A) and right (B) middle cerebral arteries in triplex mode (A). 
High and asymmetric Vs (105 cm/s and 119 cm/s) are determined in the middle cerebral arteries. 
Figure 3. Parameters of reactivity coefficient (Rc) to the CO2, O2 and 
FMt test in a patients with TTH. 
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Figure 4. Parameters of reactivity coefficient (Rc) to the orthostatic test (Ot),               
antiorthostatic test (AOt) and functional nitroglycerin test (FNt) in a patients with 
TTH. 
Figure 5. Dynamics of headache frequency in a patients with TTH during treatment 
with Phenibut 
Figure 6. Dynamics of headache intensity frequency in a patients with TTH             
during treatment with Phenibut 
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from the figure, the headache intensity in all groups 
decreased statistically insignificantly. 
 The dynamics of pain in the pericranial muscles 
before and after treatment is presented in Figure 7.  As 
can be seen from figure, according to the visual 
analogue scale (VAS) , the degree of pain in the 
pericranial muscles decreased in all clinical groups, 
however, the minimal statistical significance (P<0,05) 
was observed only in patients with chronic TTH (from 
3.3±0.3 points to 2.4±0.2 points). 
 The pharmacotherapeutic effect of Noofen on 
the dynamics of blood flow indices in the main cerebral 
arteries is shown in Figure 8. The average value of the 
Vs in all groups before and after treatment was 
differented not significantly. 
 The pharmacotherapeutic effect of  drug on the 
dynamics of blood flow indices in the vertebral and basal 
arteries before and after treatment is shown in Figure 9. 
The minimal statistical significance (P<0,05) was 
observed only  in the VA (from 41.4±1.3 cm/s to 
37.2±1.4 cm/s).  
 The results of Phenibut on vascular reactivity 
parameters are shown in figure 10. To a greater extent, 
the effect of the drug was manifested at the initially 
increased RcFMt and RcCO2. A decrease in initially 
elevated RcCO2 was noted in all clinical groups: from 
1.43±0.05 to 1.38±0.04 in patients with FE TTH; from 
1.39±0.05 to 1.37±0.06 in patients with ChTTH and 
from 1.37±0.04 to 1.35±0.05 in patients with IFE TTH. 
RcFMt decreased from 1.24±0.03 to 1.19±0.02 in 
patients with IFETTH and from 1.25±0.04 to 1.19±0.02 
in patients with FETTH (almost reaching normal values). 
RсCO2 also decreased in patients with ChTTH - from 
1.39 ± 0.07 to 1.37 ± 0.04 - almost to normal values. 
 An increase in initially reduced RCO2 coefficients 
was recorded in patients with FETTH and ChTTH (from 
0.38 ± 0.04 to 0.42 ± 0.05 and from 0.35 ± 0.05 to 
0.41 ± 0.03, respectively). The results of the studies 
indicate that, by analogy with the dynamics of cerebral 
blood flow, Phenibut  has a regulating effect on 
cerebrovascular reactivity coefficients, reducing initially 
elevated and increasing initially decreased rates. 
 When performing orthostatic and hypercapnic 
load, a similar (identical) auto-regulating effect of 
Noofen on vascular reactivity was found. The initially 
increased RcOt in patients with FETTH decreased from 
0.18±0.03 to 0.14±0.2 and from 0.19±0.04 to 
0.14±0.03 in patients with ChTTH. No significant 
changes were observed in initially close to the normative 
indicators in patients with IFETTH, which once again 
confirms the selectivity of the influence of Noofen on the 
mechanisms of vascular autoregulation. A similar picture 
was characteristic of the initially close to the standard 
parameters of RcAOt and RcFNt (Fig. 11).  
 Thus, the effectiveness of Phenibut 
(Noophen® JSC Olainfarm, Latvia) is manifested in a 
decrease in the frequency of headaches, tension in the 
pericranial muscles, especially in patients with ChTTH, 
which, in Doppler studies, are reflected in a has a 
regulate on cerebrovascular reactivity coefficients.   
Figure 7. Dynamics of indicators of pericranial soreness muscles in a patients 
with TTH during treatment with Phenibut 
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Figure 8. Dynamics of Vs in MCA, ACA, PCA in a patients with TTH during treatment with Noofen 
Figure 9. Dynamics of Vs in VA and BA in a patients with TTH during treatment with Noofen 
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Figure 10. Dynamics of RcCO2, RcO2 and RcFMt in a patients with TTH during treatment 
with Noofen 
Figure 11. Dynamics of RcOt, RcAOt and RcFNt in a patients with TTH during treatment 
with Noofen 
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Discussion 
 Tension-type headache (TTH) is the most 
common type of primary headaches, and its chronic 
form, chronic tension-type headache (CTTH), is affecting 
0.5 to 4.8 % of the worldwide population. In                
pathogenesis of chronic tension-type headache the 
leading role is assigned to the central and peripheral 
mechanisms [18].    
 By its very definition according to the Interna-
tional Classification of Headache Disorders, third edition 
(beta version) (ICHD-3 beta), CTTH is defined as the 
occurrence of TTH at a frequency of ≥15 days per 
month, with typically bilateral, pressing, or tightening in 
quality, and of mild to moderate intensity, lasting hours 
to days, or unremitting. The pain does not worsen with 
routine physical activity but may be associated with mild 
nausea, photophobia, or phonophobia [19]. 
 The exact pathogenesis of TTH remains unclear. 
Generally, peripheral mechanisms and central mecha-
nisms are intermingled in TTH. The central mechanisms 
such as central sensitization might predominate in CTTH.  
Possible peripheral mechanisms leading to pericranial 
muscle tenderness and pressure pain include inflamma-
tory reaction, decreased blood flow, increased muscle 
activity, and muscle atrophy. Lots of previous studies 
have provided in vivo evidences of peripheral muscle 
abnormal metabolism in the pathophysiology of                 
CTTH [14]. 
 Pharmacological therapies for CTTH can be 
subdivided into the abortive treatment of each acute 
exacerbation and longterm, prophylactic treatment. 
CTTH is generally treated with analgesics or nonsteroidal 
anti-inflammatory drugs [20-22]. Antidepressants, 
antispasmodic, new antiepileptics, and some local 
injections are commonly prescribed options for 
prophylactic treatment [23]. 
 It has been established that arterial partial 
pressure alteration of CO2 affects not only the cerebral 
blood flow velocity but also the systemic arterial blood 
pressure (ABP). At the same time, ABP can affect the 
cerebral blood flow [24].  
 Phenibut (beta-phenyl-gamma-aminobutyric acid 
HCl) is a neuropsychotropic drug that was discovered 
and introduced into clinical practice in Russia in the 
1960s. It has anxiolytic and nootropic effects. It also 
stimulates dopamine receptors and antagonizes                              
beta-phenethylamine (PEA), a putative endogenous 
anxiogenic. Phenibut is widely used in Russia to relieve 
tension, anxiety, and fear [25, 17]. 
 In USA Phenibut is Unscheduled. Phenibut is 
available as a nutritional supplement as it meets the 
criteria of the Dietary Supplement Health and Education 
Act 1994 (DSHEA) as a synthetic amino acid derivative. 
It is usually promoted with health maintenance claims 
(eg, helps to keep you calm) instead of disease state or 
condition claims (eg, reduces anxiety) (Cutter 2016, 
Owen et al, 2016) [26]. 
 We also studied the role of autoregulatory 
mechanisms in patients with chronic TTH using CO2, O2, 
metabolic and nitroglycerin functional tests. The results 
of our studies in patients with IFE TTH showed a slight 
hyperreactivity on the CO2-test, which confirms the 
postulate of the intensity of the humoral-metabolic 
mechanism and allows us to recommend the use of FMt 
and CO2-test in patients with a slightly manifestation of 
cephalgic syndrome. Evaluation of the regulatory 
response to respiratory loads allows identifying the 
leading reactivity patterns in various variants of                    
TTH - the complication of the vasodilator mechanism in 
ETTH and depletion vasoconstrictor mechanism with 
ChTTH. 
 When conducting a literary search on the 
subject of TTH pharmacotherapy, we did not find papers 
on drugs affecting the vascular mechanisms of headache 
development. We decided to study the effectiveness of 
Phenibut (Noophen® JSC Olainfarm, Latvia)  in the 
treatment of various forms tension-type headach. In 
addition to clinical symptoms, we recorded blood flow in 
the main cerebral arteries using Doppler sonography. In 
recently published articles, we have shown the role of 
Doppler sonography in the assessment of hemodynamics 
in brain vessels in migraines and in vertebral arteries in 
cervicogenic headache [27-29]. 
Conclusion 
 In patients with TTH, an increase in the Vs is 
more often recorded, their asymmetry in the middle 
cerebral artery. Hyperreactivity on CO2-load is typical for 
patients with chronic TTH, and reflects the mobilization 
of metabolic regulation of cerebral blood flow. 
Conducting FMt was the most informative method for 
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detecting autoregulatory disorders mainly  in patients 
with IFE TTH. FE TTH in patients is characterized by the 
presence of a hyperactive reaction to hypercapnic and 
orthostatic tests, probably due to mobilization of 
humoral-metabolic and neurogenic links of regulation. In 
the group of patients with chronic TTH prevails 
hyporeactivity for hyperventilation test, reflecting the 
depletion of vasoconstriction reserve. The use of 
Phenibut [(Noophen® (JSC Olainfarm, Latvia] in the 
treatment of TTH is accompanied by a decrease in the 
frequency of pain, and of pericranial muscle tone, most 
pronounced in patients with FE TTH. It's effectiveness is 
evident in the normalization of the  coefficients of 
cerebrovascular reactivity in a patients with chronic TTH. 
The minimal statistical significance was observed on the 
dynamics of blood flow only  in the VA. 
Comments 
 The results of our research have not shown high 
efficacy of Phenibit in TTH. However, the absence of 
side effects of the drug and the presence of a positive 
trend with minimal statistical reliability for some clinical 
symptoms and Doppler results, more in-depth studies 
with the involvement of a large number of patients, 
biochemical tests are needed to study the pathogenic 
mechanisms of its action. 
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